Novel antihypertensive therapies: Renal sympathetic nerve ablation and carotid baroreceptor stimulation

Current Hypertension Reports

Volumn 14, Issue 6, 2012, Pages 567-572

  Grassi, Guido ^a,b,c   Seravalle, Gino ^a   Brambilla, Gianmaria ^a   Bombelli, Michele ^a   Dell'Oro, Raffaella ^a   Gronda, Edoardo ^a,b   Mancia, Giuseppe ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

Blood pressure; Carotid baroreceptor stimulation; End organ damage; Hypertension; Insulin; Interventions; Renal denervation; Resistant hypertension; Side effects

Indexed keywords

GLICLAZIDE; METFORMIN;

ABLATION THERAPY; ANTIHYPERTENSIVE THERAPY; ARTERY DISSECTION; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CAROTID SINUS PRESSORECEPTOR; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FALSE ANEURYSM; GLOMERULUS FILTRATION RATE; GLUCOSE TOLERANCE TEST; HEART HEMODYNAMICS; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; HYPOTENSION; INSULIN RESISTANCE; INTERMETHOD COMPARISON; KIDNEY; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; MICROALBUMINURIA; NERVE INJURY; RESPIRATORY FAILURE; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; WOUND COMPLICATION;

CAROTID SINUS; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; KIDNEY; PRESSORECEPTORS; SYMPATHECTOMY;

EID: 84870499592     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0312-5     Document Type: Article

References (28)

1. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610-8.
2. Mancia G, De Backer G, Dominiczak A, Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87. The document includes the most recent recommendations on diagnosis and treatment of hypertension made by European experts.
3. Scheffers IJ, Kroon AA, de Leeuw PW. Carotid baroreflex activation: past, present and future. Curr Hypertens Rep. 2010;12:61-6.
4. Katholi RE, Rocha-Singh KJ, Goswami NJ, Sobotka PA. Renal nerves in the maintenance of hypertension. a potential therapeutic target. Curr Hypertens Rev. 2010;12:196-204.
5. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001;19:2063-70.
6. Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens. 2007;25:747-50.
7. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens. 2007;25:891-4.
8. Chapman N, Chang CL, Dahlöf B, Sever PS, Wedel H, Poulter NR, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118:42-8.
9. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-19. The document by the American Heart Association and High Blood Pressure Council provides important recommendations and useful flowcharts on how to diagnose and manage resistant hypertension.
10. Václavík J, Sedlák R, Plachý M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069-75.
11. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54:690-7.
12. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens. 2010;23:1052-8.
13. Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619-26. This is the first report on the acute sympathoihibitory effects of carotid baroreflex activation in resistant hypertension.
14. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-4.
15. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81. This is the first report on the blood pressure lowering effects of renal denervation in resistant hypertension.
16. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-9. The paper reports the results of the first randomized investigation on renal denervation.
17. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebocontrolled Rheos pivotal trial. J Am Coll Cardiol. 2011;58:765-73. This is the first randomized study assessing the effects of carotid baroreceptor stimulation in resistant hypertension.
18. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7.
19. Krum H, Barman N, Schlaich M, et al. Long-term follow-up of catheter-based renal denervation for resistant hypertension confirms durable reduction of blood pressure values. J Am Coll Cardiol. 2012;59:E1704.
20. Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation -an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837-41.
21. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940-6. The results of this study provide evidence on the favorable metabolic effects of carotid baroreceptor activation.
22. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-65.
23. Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29:991-6.
24. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901-9.
25. Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P, et al. Improved cardiac structure and function with chronic tretament using an implantable device in resistant hypertension: results from european and United States Trials of the Rheos System. J Am Coll Cardiol. 2011;57:1787-8.
26. Hering D, Mahfoud F, Walton As, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:pages to be determined.
27. Scheffers IJM, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56:1254-8.
28. Deming QB, Luetscher Jr. JA. Increased sodium-retaining corticoid excretion in edema, with some observations on the effects of cortisone in nephrosis. J Clin Invest. 1950;29:808.